Header Logo

Connection

PEDRO PIEDRA to Child

Back to Details
This is a "connection" page, showing publications PEDRO PIEDRA has written about Child.
PEDRO PIEDRA
Connection Strength
0.739
Child
  1. Single cell sequencing analysis of respiratory syncytial virus-infected pediatric and adult human nose organoids reveals age differences, proliferative diversity and identifies novel cellular tropism. J Infect. 2025 Oct; 91(4):106617.
    View in: PubMed
    Score: 0.057
  2. Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein. Vaccine. 2022 01 24; 40(3):536-543.
    View in: PubMed
    Score: 0.044
  3. Premature Infants With Respiratory Syncytial Virus (RSV): The Need for Both Maternal and Pediatric RSV Prevention Strategies. J Infect Dis. 2020 09 01; 222(7):1070-1072.
    View in: PubMed
    Score: 0.040
  4. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. 2020 08; 39(8):700-705.
    View in: PubMed
    Score: 0.040
  5. Long-Term Healthcare Costs Associated With Respiratory Syncytial Virus Infection in Children: The Domino Effect. J Infect Dis. 2020 03 28; 221(8):1205-1207.
    View in: PubMed
    Score: 0.039
  6. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010 Dec 01; 202(11):1626-33.
    View in: PubMed
    Score: 0.020
  7. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009 Jul; 124(1):170-8.
    View in: PubMed
    Score: 0.018
  8. Societal and economic consequences of influenza. Manag Care. 2008 Oct; 17(10 Suppl 10):8-14.
    View in: PubMed
    Score: 0.017
  9. The search for adenovirus 14 in children in Houston, Texas. Pediatr Infect Dis J. 2008 Jul; 27(7):653-4.
    View in: PubMed
    Score: 0.017
  10. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep; 120(3):e553-64.
    View in: PubMed
    Score: 0.016
  11. Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatr Pulmonol. 2007 Jan; 42(1):66-74.
    View in: PubMed
    Score: 0.015
  12. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005 Sep; 116(3):e397-407.
    View in: PubMed
    Score: 0.014
  13. Epidemiology and genotypic diversity of rhinovirus in school-age children with acute respiratory illnesses seeking medical care. J Clin Virol. 2025 Aug; 179:105806.
    View in: PubMed
    Score: 0.014
  14. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18; 23(13):1540-8.
    View in: PubMed
    Score: 0.014
  15. Influenza C virus in U.S. children with acute respiratory infection 2016-2019. J Clin Virol. 2024 10; 174:105720.
    View in: PubMed
    Score: 0.013
  16. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
    View in: PubMed
    Score: 0.013
  17. Genome type analysis of adenovirus types 3 and 7 isolated during successive outbreaks of lower respiratory tract infections in children. J Clin Microbiol. 2003 Oct; 41(10):4594-9.
    View in: PubMed
    Score: 0.012
  18. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003 Jul 28; 21(24):3479-82.
    View in: PubMed
    Score: 0.012
  19. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine. 2003 Jun 02; 21(19-20):2448-60.
    View in: PubMed
    Score: 0.012
  20. Sustained Within-season Vaccine Effectiveness Against Influenza-associated Hospitalization in Children: Evidence From the New Vaccine Surveillance Network, 2015-2016 Through 2019-2020. Clin Infect Dis. 2023 02 08; 76(3):e1031-e1039.
    View in: PubMed
    Score: 0.012
  21. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J. 2003 Feb; 22(2 Suppl):S94-9.
    View in: PubMed
    Score: 0.012
  22. Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan. BMC Pediatr. 2023 01 21; 23(1):35.
    View in: PubMed
    Score: 0.012
  23. Clinical Presentation and Severity of Adenovirus Detection Alone vs Adenovirus Co-detection With Other Respiratory Viruses in US Children With Acute Respiratory Illness from 2016 to 2018. J Pediatric Infect Dis Soc. 2022 Oct 25; 11(10):430-439.
    View in: PubMed
    Score: 0.012
  24. Comparative analysis of three multiplex platforms for the detection of respiratory viral pathogens. J Clin Virol. 2022 11; 156:105274.
    View in: PubMed
    Score: 0.011
  25. Future directions in vaccine prevention of respiratory syncytial virus. Pediatr Infect Dis J. 2002 May; 21(5):482-7.
    View in: PubMed
    Score: 0.011
  26. Novel and extendable genotyping system for human respiratory syncytial virus based on whole-genome sequence analysis. Influenza Other Respir Viruses. 2022 05; 16(3):492-500.
    View in: PubMed
    Score: 0.011
  27. Severe bronchiolitis profiles and risk of asthma development in Finnish children. J Allergy Clin Immunol. 2022 04; 149(4):1281-1285.e1.
    View in: PubMed
    Score: 0.011
  28. Comparison of Mid-Turbinate and Nasopharyngeal Specimens for Molecular Detection of SARS-CoV-2 Among Symptomatic Outpatients at a Pediatric Drive-Through Testing Site. J Pediatric Infect Dis Soc. 2021 Sep 23; 10(8):872-879.
    View in: PubMed
    Score: 0.011
  29. Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. Vaccine. 2021 07 05; 39(30):4063-4071.
    View in: PubMed
    Score: 0.011
  30. Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerg Infect Dis. 2021 06; 27(6):1-9.
    View in: PubMed
    Score: 0.011
  31. Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort'. Ann Rheum Dis. 2022 12; 81(12):e239.
    View in: PubMed
    Score: 0.010
  32. Respiratory syncytial virus vaccines: recent developments. Pediatr Infect Dis J. 2000 Aug; 19(8):805-8; discussion 809-10.
    View in: PubMed
    Score: 0.010
  33. Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study. Pediatr Infect Dis J. 2020 08; 39(8):706-712.
    View in: PubMed
    Score: 0.010
  34. Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma. J Allergy Clin Immunol Pract. 2020 02; 8(2):588-595.e4.
    View in: PubMed
    Score: 0.009
  35. Association of type 2 cytokines in severe rhinovirus bronchiolitis during infancy with risk of developing asthma: A multicenter prospective study. Allergy. 2019 07; 74(7):1374-1377.
    View in: PubMed
    Score: 0.009
  36. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J. 1998 Mar; 17(3):217-24.
    View in: PubMed
    Score: 0.008
  37. Isolation of adenovirus type 7 from the urine of children with acute hemorrhagic cystitis. Pediatr Infect Dis J. 1996 Jul; 15(7):633-4.
    View in: PubMed
    Score: 0.007
  38. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
    View in: PubMed
    Score: 0.007
  39. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J. 1996 Jan; 15(1):23-31.
    View in: PubMed
    Score: 0.007
  40. Influenza virus pneumonia: pathogenesis, treatment, and prevention. Semin Respir Infect. 1995 Dec; 10(4):216-23.
    View in: PubMed
    Score: 0.007
  41. Factors associated with real-time RT-PCR cycle threshold values among medically attended influenza episodes. J Med Virol. 2016 Apr; 88(4):719-23.
    View in: PubMed
    Score: 0.007
  42. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine. 1995 Aug; 13(12):1095-101.
    View in: PubMed
    Score: 0.007
  43. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
    View in: PubMed
    Score: 0.007
  44. Racial/ethnic differences in the presentation and management of severe bronchiolitis. J Hosp Med. 2014 Sep; 9(9):565-72.
    View in: PubMed
    Score: 0.006
  45. Detection of NH1N1 influenza virus in nonrespiratory sites among children. Pediatr Infect Dis J. 2014 Jan; 33(1):95-6.
    View in: PubMed
    Score: 0.006
  46. Nasopharyngeal Proteobacteria are associated with viral etiology and acute wheezing in children with severe bronchiolitis. J Allergy Clin Immunol. 2014 Apr; 133(4):1220-2.
    View in: PubMed
    Score: 0.006
  47. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
    View in: PubMed
    Score: 0.006
  48. Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177.
    View in: PubMed
    Score: 0.006
  49. [Universal immunisation against influenza in paediatrics, yes or no?]. An Pediatr (Barc). 2013 Oct; 79(4):261.e1-261.e11.
    View in: PubMed
    Score: 0.006
  50. Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illness. J Clin Microbiol. 2012 Feb; 50(2):506-8.
    View in: PubMed
    Score: 0.005
  51. Incidence of catheter-associated gram-negative bacteremia in children with short bowel syndrome. J Clin Microbiol. 1989 Jun; 27(6):1317-9.
    View in: PubMed
    Score: 0.005
  52. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May; 27(5):444-52.
    View in: PubMed
    Score: 0.004
  53. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007 May 16; 25(20):4038-45.
    View in: PubMed
    Score: 0.004
  54. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan; 158(1):65-73.
    View in: PubMed
    Score: 0.003
  55. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003 Aug 15; 158(4):305-11.
    View in: PubMed
    Score: 0.003
  56. Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis. Clin Infect Dis. 2001 May 15; 32(10):1423-9.
    View in: PubMed
    Score: 0.003
  57. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis. 2000 Jun; 181(6):1891-6.
    View in: PubMed
    Score: 0.002
  58. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000 Mar; 181(3):1133-7.
    View in: PubMed
    Score: 0.002
  59. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000 Feb; 136(2):168-75.
    View in: PubMed
    Score: 0.002
  60. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000 Jan 26; 283(4):499-505.
    View in: PubMed
    Score: 0.002
  61. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1998 Nov; 27(5):1194-200.
    View in: PubMed
    Score: 0.002
  62. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med. 1997 Mar 17; 102(3A):61-70; discussion 75-6.
    View in: PubMed
    Score: 0.002
  63. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1994 Oct; 125(4):635-41.
    View in: PubMed
    Score: 0.002
  64. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol. 1991 Feb 01; 133(3):296-304.
    View in: PubMed
    Score: 0.001
  65. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1990 Aug; 117(2 Pt 1):313-20.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.